Safran's deepening demand resets the growth ladder
Order book crosses $1B on aerospace expansion; Street sees 25% upside as margins face test from capital investment cycle.
Aequs Ltd enters Q2 FY-2027 on the back of a transformative six months for aerospace. The October 2026 Safran announcements — expanding beyond landing gear into aerosystems and defence electronics — come on the heels of the July A320 wheels deal (15+ years, through 2042). Revenue momentum remains crisp: Q1 FY27 hit ₹395.5 Cr, up 55% YoY. The order book has now crossed $1B, providing multi-year visibility across Airbus and Boeing programmes. The Street is bullish — consensus buy rating with ₹305 average 12-month target (+25% upside). But Q2 will test one critical assumption: can margins hold while capex and setup costs ramp?
~₹1,940 Cr
+57.8% YoY; Q1 delivery ₹396 Cr on track; Safran deals add medium-term tailwind
>$1B
New milestone post-Safran; multi-year OEM visibility across A320, A330, A350, 787
TBD
Q1 showed revenue momentum; watch for EBITDA recovery as utilization scales post-capex phase
₹-0.85
Loss expected due to expansion costs; dilution from ₹650 Cr warrant issuance approved Sep 25
A strong Q2 would show revenue momentum sustained (₹400+ Cr range) with EBITDA margin stabilizing or improving as aerospace utilization ticks up and fixed-cost absorption widens. Weak would mean revenue in-line but EBITDA under pressure — signal that capex, integration, and ramp costs are running hotter than guided. Promoter financing activity (₹200 Cr pledge for loans in Sep–Oct, ₹650 Cr warrant issuance) underscores confidence in the plan but flags near-term EPS dilution.
On Track?
Aequs is executing on the aerospace supercycle. Q1 FY27's 55% YoY growth and the $1B order book mark a step-change versus prior years. The Safran contracts (October 2026) are not incremental; they reset the growth baseline by adding electrons and aerosystems to the prior landing-gear focus. If the company sustains 50%+ revenue growth through FY27 and reaches the ₹1.94k Cr full-year target, full-year guidance is on track. The debate is not top-line — it is whether margin expansion lags as capex peaks.
Since Last Quarter
1 · Safran Long-Term Contracts (Oct 12, 2026)
Expansion signal. Aequs signed multi-year supply agreements with Safran Aerosystems and Safran Electronics & Defense for machining superalloys and flight-critical components — extending beyond the July A320 wheels deal. Covers A320, A330, A350, and Boeing 787 programmes. No revenue guidance in the announcement, but analysts view it as validation of Aequs' manufacturing capability and widening OEM trust.
2 · Board Meeting & Result Timeline (Oct 26, 2026)
Routine. Board convenes on result day to approve unaudited Q2 FY27 results. Trading window was closed from Sep 25 onwards, now re-opening post-result.
3 · Preferential Warrant Issue (Sep 25, 2026)
Dilution watch. Board approved ₹650 Cr issuance of 2.81 Cr warrants at ₹231.55 each to the promoter group (Mellwood Trustee Services). Conditional conversion clause; dilution to EPS once exercised. EGM held Oct 22 to seek shareholder approval. Signals aggressive capex financing for aerospace capacity expansion.
4 · Promoter Pledge Activity (Sep–Oct 2026)
Leverage signal. Melligeri Private Family Foundation (promoter) pledged 14.99% of shares (10.05 Cr shares) for ₹200 Cr financing in September–October. Reflects capital requirement to fund growth capex and working capital. Pledge release (Oct 10) followed by re-pledge (Oct 16) suggests active liquidity management. Risk: high promoter leverage if execution slips.
5 · Amalgamation Scheme Rejected (Oct 13, 2026)
Corporate structure unchanged. Regional Director rejected the scheme to merge Aequs with its wholly-owned subsidiaries (AeroStructures, Engineered Plastics, Force Consulting). No direct revenue impact; confirms Aequs will remain consolidated group. May delay some tax or legal efficiencies but does not alter operational strategy.
What to Watch on Result Day (Oct 26)
1 · Revenue & Growth Rate
Absolute Q2 revenue, YoY growth rate (track against Q1's 55% pace). Sequential QoQ growth is secondary but worth noting for seasonality. If aerospace is >50% of revenue mix and growing faster, that's a clean signal of mix-shift upside.
2 · EBITDA Margin & EPS
Watch EBITDA margin vs Q1 and prior-year Q2. Consensus expects FY27 EPS of -₹0.85; Q2 will show how much loss is front-loaded (capex heavy H1) vs deferred. Margin trajectory is the key investor debate — if margin compresses YoY despite revenue growth, Street will probe for timing of margin recovery.
3 · Capex & Cash Burn
Management commentary on capex phasing, expected completion timeline for Safran setup, and working-capital needs. The ₹200 Cr pledge and ₹650 Cr warrant raise imply heavy investment; confirm target capex run-rate and when return on incremental assets kicks in.
4 · Safran Revenue Ramp & Guidance
Any quantification of Safran revenues expected in H2 FY27 or FY28? The October contracts are new; Q2 unlikely to have meaningful Safran aerospace revenue yet (ramp is gradual). Listen for management confidence on FY27 target sustainability and whether ₹1.94k Cr guide is reiterated or adjusted.
Aequs is a story of aerospace-led acceleration and margin recovery patience. The Safran deals (October 2026) confirm that OEMs view Aequs as a credible sourcing alternative — a decisive shift from legacy consumer-electronics roots. With >$1B order book and 15+ year wheel supply locked through 2042, long-term earnings potential is real. The risk is execution: can capex be absorbed and margins recovered while Safran volumes ramp? Q2 will show whether Q1's 55% revenue momentum sustains and where EBITDA margin bottoms as expansion costs peak. Street consensus is bullish (+25% average target), but Q2 earnings call and guidance will determine if margin recovery timeline (and thus valuation) is credible.
Result date: October 26, 2026. Watch revenue momentum, EBITDA margin trajectory, and management capex guidance.